Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers

Hessell, A J; Rakasz, E G; Poignard, P; Hangartner, L; Landucci, G; Forthal, D N; Koff, W C; Watkins, D I; Burton, D R

doi:10.1371/journal.ppat.1000433

Citations

Citation copied

Hessell, A. J., Rakasz, E. G., Poignard, P., Hangartner, L., Landucci, G., Forthal, D. N., Koff, W. C., Watkins, D. I., & Burton, D. R. (2009). Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathogens, 5(5), e1000433. https://doi.org/10.1371/journal.ppat.1000433

Abstract

Developing an immunogen that elicits broadly neutralizing antibodies (bNAbs) is an elusive but important goal of HIV vaccine research, especially after the recent failure of the leading T cell based HIV vaccine in human efficacy trials. Even if such an immunogen can be developed, most animal model studies indicate that high serum neutralizing concentrations of bNAbs are required to provide significant benefit in typical protection experiments. One possible exception is provided by the anti-glycan bNAb 2G12, which has been reported to